Journey Medical Corp (DERM) stock
DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% below fair value
$4.33−0.06 (-1.37%)
Close on Nov 13, 2026Market cap $122.21MP/E –Yield –
Earnings
Journey Medical's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 24, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$19.00M
+8.0% on a year earlier
Non-GAAP Adjusted EBITDA, Q3 FY2026
$0.12
$0.06 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Journey Medical's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 24, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 12, 2026after the close | $19.00M | +8.0% | -$0.05 | $0.12 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 12, 2026after the close | $18.50M | +23.3% | -$0.01 | $0.10 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 13, 2026after the close | $16.00M | +22.1% | -$0.08 | $0.02 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 25, 2026after the close | $61.90M | – | -$0.47 | $0.10 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 12, 2025after the close | $17.60M | +20.5% | -$0.09 | $0.06 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 12, 2025after the close | $15.00M | +0.7% | -$0.16 | -$0.02 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 14, 2025after the close | $13.10M | +0.8% | -$0.18 | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 26, 2025after the close | – | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024after the close | $14.60M | -57.7% | -$0.12 | $0.01 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 12, 2024after the close | $14.90M | -13.4% | -$0.17 | $0.01 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 13, 2024after the close | $13.00M | – | -$0.53 | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 21, 2024after the close | – | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023after the close | $34.50M | – | $0.80 | $0.99 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023after the close | $17.20M | -6.0% | -$0.46 | -$0.04 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 29, 2023after the close | $16.00M | -8.6% | -$0.60 | -$0.17 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022after the close | – | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022after the close | $18.30M | – | -$0.43 | -$0.15 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022after the close | $23.30M | – | -$0.08 | $0.11 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 24, 2022after the close | $17.50M | – | -$1.64 | -$0.93 | Release |
| Q3 FY2021ended Sep 30, 2021 | Dec 10, 2021after the close | $19.60M | – | -$1.16 | $0.32 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Journey Medical has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Journey Medical puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Journey Medical filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- Results
- Results
- Results
- News
- News
- Results
- Results
- News
- Results
- Results
- Results
See a number that looks wrong?